Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 38

1.

Partnering for therapeutics discovery.

Colvis CM, Devaney S, Brady LS, Hudson KL.

Clin Pharmacol Ther. 2013 Jan;93(1):24-5. doi: 10.1038/clpt.2012.188. Epub 2012 Nov 28. Review. No abstract available.

PMID:
23187876
[PubMed - indexed for MEDLINE]
2.

Mining for therapeutic gold.

Collins FS.

Nat Rev Drug Discov. 2011 Jun;10(6):397. doi: 10.1038/nrd3461. Review.

PMID:
21629277
[PubMed - indexed for MEDLINE]
3.

Opinion: anticipating change in drug development: the emerging era of translational medicine and therapeutics.

Fitzgerald GA.

Nat Rev Drug Discov. 2005 Oct;4(10):815-8. Review.

PMID:
16224453
[PubMed - indexed for MEDLINE]
4.

The future is much closer collaboration between the pharmaceutical industry and academic medical centers.

Vallance P, Williams P, Dollery C.

Clin Pharmacol Ther. 2010 May;87(5):525-7. doi: 10.1038/clpt.2010.29. Review. No abstract available.

PMID:
20407455
[PubMed - indexed for MEDLINE]
5.

An industrial perspective on contemporary applications of PBPK models in drug discovery and development.

Smith BJ.

Biopharm Drug Dispos. 2012 Mar;33(2):53-4. doi: 10.1002/bdd.1778. Epub 2012 Mar 12. Review. No abstract available.

PMID:
22407480
[PubMed - indexed for MEDLINE]
6.

Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap.

Pratt J, Winchester C, Dawson N, Morris B.

Nat Rev Drug Discov. 2012 Jun 22;11(7):560-79. doi: 10.1038/nrd3649. Review.

PMID:
22722532
[PubMed - indexed for MEDLINE]
7.

The biomarker is not the end.

Nohaile M.

Drug Discov Today. 2011 Oct;16(19-20):878-83. doi: 10.1016/j.drudis.2011.08.011. Epub 2011 Aug 24. Review.

PMID:
21888986
[PubMed - indexed for MEDLINE]
8.

The risky business of drug development in neurology.

Craven R.

Lancet Neurol. 2011 Feb;10(2):116-7. doi: 10.1016/S1474-4422(11)70004-7. Review. No abstract available.

PMID:
21256451
[PubMed - indexed for MEDLINE]
9.

Toward personalized medicine in the neuropsychiatric field.

Wong EH, Fox JC, Ng MY, Lee CM.

Int Rev Neurobiol. 2011;101:329-49. doi: 10.1016/B978-0-12-387718-5.00013-4. Review.

PMID:
22050858
[PubMed - indexed for MEDLINE]
10.

What matters most in commercial success: first-in-class or best-in-class?

Schulze U, Ringel M.

Nat Rev Drug Discov. 2013 Jun;12(6):419-20. doi: 10.1038/nrd4035. Review. No abstract available.

PMID:
23722339
[PubMed - indexed for MEDLINE]
11.

Deconstructing the drug development process: the new face of innovation.

Kaitin KI.

Clin Pharmacol Ther. 2010 Mar;87(3):356-61. doi: 10.1038/clpt.2009.293. Epub 2010 Feb 3. Review. No abstract available. Erratum in: Clin Pharmacol Ther. 2011 Jan;89(1):148.

PMID:
20130565
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science.

Woosley RL, Myers RT, Goodsaid F.

Clin Pharmacol Ther. 2010 May;87(5):530-3. doi: 10.1038/clpt.2010.27. Review.

PMID:
20407457
[PubMed - indexed for MEDLINE]
13.

[Positron emission tomography as a research tool for translational science].

Nishimura S.

Nihon Yakurigaku Zasshi. 2013 Mar;141(3):136-40. Review. Japanese. No abstract available.

PMID:
23470478
[PubMed - indexed for MEDLINE]
14.

Drug discovery in the next decade: innovation needed ASAP.

Bennani YL.

Drug Discov Today. 2011 Sep;16(17-18):779-92. doi: 10.1016/j.drudis.2011.06.004. Epub 2011 Jun 15. Review.

PMID:
21704185
[PubMed - indexed for MEDLINE]
15.

Clinical translation of cell-based pharmacogenomic discovery.

Cox NJ, Gamazon ER, Wheeler HE, Dolan ME.

Clin Pharmacol Ther. 2012 Oct;92(4):425-7. doi: 10.1038/clpt.2012.115. Epub 2012 Aug 22. Review.

PMID:
22910437
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

How informatics can potentiate precompetitive open-source collaboration to jump-start drug discovery and development.

Perakslis ED, Van Dam J, Szalma S.

Clin Pharmacol Ther. 2010 May;87(5):614-6. doi: 10.1038/clpt.2010.21. Epub 2010 Apr 7. Review. No abstract available.

PMID:
20376001
[PubMed - indexed for MEDLINE]
17.

Developing pharmacogenetic evidence throughout clinical development.

Burns DK.

Clin Pharmacol Ther. 2010 Dec;88(6):867-70. doi: 10.1038/clpt.2010.246. Epub 2010 Oct 27. Review.

PMID:
20981004
[PubMed - indexed for MEDLINE]
18.

In search of preclinical robustness.

Peers IS, Ceuppens PR, Harbron C.

Nat Rev Drug Discov. 2012 Oct;11(10):733-4. doi: 10.1038/nrd3849. Review.

PMID:
23023666
[PubMed - indexed for MEDLINE]
19.

Strategies for bringing drug delivery tools into discovery.

Kwong E, Higgins J, Templeton AC.

Int J Pharm. 2011 Jun 30;412(1-2):1-7. doi: 10.1016/j.ijpharm.2011.03.024. Epub 2011 Mar 21. Review.

PMID:
21421040
[PubMed - indexed for MEDLINE]
20.

Tuberculosis vaccines: a strategic blueprint for the next decade.

Brennan MJ, Thole J.

Tuberculosis (Edinb). 2012 Mar;92 Suppl 1:S6-13. doi: 10.1016/S1472-9792(12)70005-7. No abstract available.

PMID:
22441160
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk